Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

Thyroid-Associated Ophthalmopathy Clinical Trial

Official title:
A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.

Status Terminated

Clinical Trial Summary

The main purpose of this study is to evaluate the efficacy and safety of 3 doses of Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and extraocular muscular contraction in patients with active thyroid-associated ophthalmopathy of moderate intensity.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Eye Diseases
Graves Ophthalmopathy
Thyroid Diseases
Thyroid-Associated Ophthalmopathy

Clinical Trial Details

NCT number	NCT00288522
Study type	Interventional
Source	Ipsen
Contact
Status	Terminated
Phase	Phase 2
Start date	January 2006
Completion date	April 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03948191` - 99Tc-MDP for Thyroid-Associated Ophthalmopathy	Phase 4
Completed	`NCT02693808` - New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression	N/A
Completed	`NCT01599273` - Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections	Phase 4
Completed	`NCT01579539` - The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy	Phase 3
Recruiting	`NCT02203682` - Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy	Phase 2
Completed	`NCT01868997` - Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease	Phase 2
Recruiting	`NCT04936854` - Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease	Phase 2
Completed	`NCT00595335` - Trial of Rituximab for Graves' Ophthalmopathy	Phase 2/Phase 3